St. Jude Children's Research Hospital scientist named Pew-Stewart Scholar

June 09, 2016

Paul A. Northcott, Ph.D., of St. Jude Children's Research Hospital has been named a Pew-Stewart Scholar for Cancer Research, a program that supports young, innovative cancer researchers.

Northcott is an assistant member of the St. Jude Department of Developmental Neurobiology, whose research focuses on medulloblastoma, the most common malignant pediatric brain tumor. His projects include using genome sequencing techniques to understand why medulloblastoma recurs. The findings from these studies should aid development of much-needed therapies for patients who relapse.

"This announcement continues a long legacy of support from Pew Charitable Trusts and its partners for St. Jude researchers at different stages of their careers," said James R. Downing, M.D., St. Jude president and chief executive officer. "At St. Jude, we value that support, which helps early career researchers like Dr. Northcott tackle fundamental scientific questions, including unanswered questions in cancer biology, and use those insights to fill gaps in our understanding and treatment of medulloblastoma and other pediatric cancers."

Northcott is one of five new Pew-Stewart Scholars who were selected based on their dedication to pursuing innovative leads to cure cancer. The award includes four years of research funding. The program is a partnership between the Pew Charitable Trusts and the Alexander and Margaret Stewart Trust.

Northcott earned his doctorate at the University of Toronto, where he also completed his first postdoctoral fellowship at the Hospital of Sick Children. He completed a second postdoctoral fellowship at the German Cancer Research Center in Heidelberg working with Stefan Pfister, M.D. Northcott joined St. Jude in 2015.
-end-


St. Jude Children's Research Hospital

Related Medulloblastoma Articles from Brightsurf:

Cerebrospinal fluid as liquid biopsy for characterizing & policing of medulloblastoma
Building on previous research led by Joan Seoane, Director of Translational Research at the Vall d'Hebron Institute of Oncology (VHIO) and ICREA Research Professor, latest findings from a proof-of-concept study published in Nature Communications, show that the analysis of cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA), allows for the more precise characterization, molecular diagnosis (including subtyping and risk stratification), and real time tracking of medulloblastoma (MB) - the most prevalent malignant brain tumor in childhood.

Researchers find potential to make brain cancers in children respond better to treatment
Research has identified a small molecule compound that can activate the Wnt pathway in non-Wnt subtypes of medulloblastoma, making these aggressive forms of cancer more responsive to therapies.

A promising new treatment for recurrent pediatric brain cancer
Researchers developed a novel approach that delivers appropriately-targeted chimeric antigen receptor (CAR) T cell therapy directly into the cerebrospinal fluid that surrounds recurrent pediatric brain tumors.

Inherited mutation can predispose children to a type of brain tumor
Collaboration co-led by researchers at St. Jude Children's Research Hospital discovers a novel predisposition gene in pediatric medulloblastoma.

Understanding brain tumors in children
The causes of 40% of all cases of certain medulloblastomas -- dangerous brain tumors affecting children -- are hereditary.

Targeting a transporter to treat SHH medulloblastoma
Scientists at St. Jude Children's Research Hospital have identified a novel target for a type of pediatric brain tumor.

Researchers identify novel potential combination therapy for childhood brain tumors
Brazilian researchers working in collaboration with Canadian scientists demonstrated that all medulloblastoma tumor subtypes express two stem cell markers: BMI1 and CD133.

Researchers identify possible approach to block medulloblastoma growth
University of North Carolina Lineberger Comprehensive Cancer Center researchers have identified a potential approach to stop the growth of the most common type of brain tumor in children.

Leukemia drug shows promise for treating a childhood brain cancer
Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego researchers describe new use of leukemia drug, nilotinib, to treat subtype of medulloblastoma, a deadly pediatric brain cancer.

Cracking the code of a brain cancer that keeps coming back
Researchers used a powerful new computer-assisted technology called single-cell transcriptomics that measures thousands of individual cells simultaneously to map cell types and molecular cascades that drive the growth of SHH-medulloblastoma.

Read More: Medulloblastoma News and Medulloblastoma Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.